长效头孢克洛（S6472）的药理及临床研究

[Pharmacological and clinical studies on the long acting cefaclor (S6472)].

作者信息

Fujimoto M, Sakai K, Ueda T, Doi S, Sasaki T, Morimoto Y, Sawada A, Masada A

出版信息

Jpn J Antibiot. 1985 Mar;38(3):849-57.

Abstract

A study in which 375 mg of S6472 was orally given to 3 healthy adult volunteers before a meal, after a light meal, and after a usual meal in the cross-over method revealed the highest levels, both in serum and urine, in cases treated before a meal. In cases administered after a light or square meal, the serum level was less, but approximately 2 micrograms/ml over 6 hours after administration. No difference was seen in the AUC. The effective rate of S6472 when given at 750 approximately 1,500 mg/day was 74.6% in 62 patients with skin or soft tissue infectious diseases. Neither subjective or objective adverse reactions were seen in any case. Clinical laboratory testing revealed 1 case each of anemia and increased BUN, for which S6472 was not responsible.

摘要

一项采用交叉给药法，让3名健康成年志愿者分别在饭前、吃便餐之后和吃正常餐之后口服375毫克S6472的研究显示，饭前服药的情况下，血清和尿液中的药物水平最高。在吃便餐或正常餐之后服药的情况下，血清水平较低，但给药后6小时内约为2微克/毫升。曲线下面积（AUC）未见差异。62例皮肤或软组织感染性疾病患者，S6472以每日约750至1500毫克给药时，有效率为74.6%。任何情况下均未出现主观或客观的不良反应。临床实验室检测发现1例贫血和1例血尿素氮升高，但均与S6472无关。